SynthesisClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Synthesis in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionVenous thromboembolism (VTE), which includes DVT and PE is a serious complication in cancer patients. This meta-analysis evaluates the efficacy and safety of rivaroxaban compared to LMWHs in treating cancer-associated VTE.MethodsFollowing PRISMA guidelines, we searched PubMed, Cochrane Library, Google Scholar, and ClinicalTrials.gov from inception to May 2025 for studies comparing rivaroxaban with low-molecular-weight heparins (LMWHs) in adults with cancer-associated VTE. Primary outcomes were VTE recurrence and all-cause mortality. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random-effects model. Risk of bias was assessed using RoB and NOS, with sensitivity and GRADE analyses performed.ResultsTwenty-five studies (n = 19,153, Rivaroxaban: 5186; LMWH: 13967) were included. Rivaroxaban significantly reduced the risk of VTE recurrence compared to LMWH (RR = 0.88; 95% CI: 0.78-0.99; P = 0.03). Rivaroxaban also significantly reduced all-cause mortality compared to LMWH (RR = 0.83; 95% CI: 0.69-0.99; P = 0.04). However, no statistically significant differences were noted in other outcomes. GRADE assessment showed evidence certainty ranged from high to very low.ConclusionRivaroxaban demonstrates lower all-cause mortality compared with LMWH, indicating a potential advantage in managing cancer-associated VTE. However, further large-scale RCTs are warranted to confirm its safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.